Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis.
Current and past drug intake is essential in the evaluation of a patient who has DAH. Simple treatments, such as reversal of a coagulation defect or withdrawal of the drug, can reverse a life-threatening situation. DAO may result in DAH, and depending on the severity of the drug withdrawl, will not be adequate and corticosteroid therapy is recommended.
Schwarz
Marvin I
MI
Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, C272, Denver, CO 80262, USA. marvin.schwarz@uchsc.edu
Fontenot
Andrew P
AP
D000925:Anticoagulants / Q000009:adverse effects; D005343:Fibrinolytic Agents / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D007049:Iatrogenic Disease; D008171:Lung Diseases / Q000139:chemically induced*; D014657:Vasculitis / Q000139:chemically induced*
D000925:Anticoagulants; D005343:Fibrinolytic Agents